High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer

Massimiliano Gennaro, Elisabetta Meneghini, Paolo Baili, Sara Bravaccini, Annalisa Curcio, Maria Carmen De Santis, Laura Lozza, Chiara Listorti, Serena Di Cosimo, Milena Sant, Secondo Folli

Research output: Contribution to journalArticle

Abstract

Background: Ductal carcinoma in situ (DCIS) is considered a morphologic precursor of invasive cancer and is often treated with adjuvant whole-breast irradiation and endocrine therapy, as if it were an invasive cancer. Our aim was to provide further support for treatment de-escalation or enrollment of such patients in active surveillance trials. Methods: We retrospectively analyzed data on patients with conservatively treated primary DCIS subsequently diagnosed with ipsilateral invasive breast cancer (IBC) at 2 comprehensive breast cancer centers. From their merged databases, we identified 50 cases with full details on tumor grade, hormone receptor expression, and HER2 amplification, for both the primary DCIS and the corresponding IBC, and we assessed the similarities and differences between the two. Results: Distributions of hormone receptors were similar in primary DCIS and IBC, while high-grade and HER2-positive status was less common in IBC than in primary DCIS. The positivity for estrogen receptors (ER) and well-differentiated or moderately differentiated morphology in the primary DCIS persisted in 90% of the matching IBC. Changes in progesterone receptor expression were slightly more common than those in ER expression. Overall consistency for the luminal-like receptors subtype was found in 90% of cases. Conclusion: The high consistency between the features of primary DCIS and those of subsequent IBC (in the rare but not negligible cases of local failure) should be borne in mind when considering the therapeutic options. Treatment de-escalation and accrual of patients for active surveillance trials could be appropriate for luminal-like precursors.

Original languageEnglish
JournalTumori
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Breast Neoplasms
Neoplasms
Estrogen Receptors
Hormones
Progesterone Receptors
Therapeutics
Breast
Databases

Keywords

  • active surveillance
  • breast cancer subtype
  • Intraductal breast cancer
  • invasive local relapse
  • treatment de-escalation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer. / Gennaro, Massimiliano; Meneghini, Elisabetta; Baili, Paolo; Bravaccini, Sara; Curcio, Annalisa; De Santis, Maria Carmen; Lozza, Laura; Listorti, Chiara; Di Cosimo, Serena; Sant, Milena; Folli, Secondo.

In: Tumori, 01.01.2019.

Research output: Contribution to journalArticle

@article{a4301c9945544950b016645cbc7ff868,
title = "High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer",
abstract = "Background: Ductal carcinoma in situ (DCIS) is considered a morphologic precursor of invasive cancer and is often treated with adjuvant whole-breast irradiation and endocrine therapy, as if it were an invasive cancer. Our aim was to provide further support for treatment de-escalation or enrollment of such patients in active surveillance trials. Methods: We retrospectively analyzed data on patients with conservatively treated primary DCIS subsequently diagnosed with ipsilateral invasive breast cancer (IBC) at 2 comprehensive breast cancer centers. From their merged databases, we identified 50 cases with full details on tumor grade, hormone receptor expression, and HER2 amplification, for both the primary DCIS and the corresponding IBC, and we assessed the similarities and differences between the two. Results: Distributions of hormone receptors were similar in primary DCIS and IBC, while high-grade and HER2-positive status was less common in IBC than in primary DCIS. The positivity for estrogen receptors (ER) and well-differentiated or moderately differentiated morphology in the primary DCIS persisted in 90{\%} of the matching IBC. Changes in progesterone receptor expression were slightly more common than those in ER expression. Overall consistency for the luminal-like receptors subtype was found in 90{\%} of cases. Conclusion: The high consistency between the features of primary DCIS and those of subsequent IBC (in the rare but not negligible cases of local failure) should be borne in mind when considering the therapeutic options. Treatment de-escalation and accrual of patients for active surveillance trials could be appropriate for luminal-like precursors.",
keywords = "active surveillance, breast cancer subtype, Intraductal breast cancer, invasive local relapse, treatment de-escalation",
author = "Massimiliano Gennaro and Elisabetta Meneghini and Paolo Baili and Sara Bravaccini and Annalisa Curcio and {De Santis}, {Maria Carmen} and Laura Lozza and Chiara Listorti and {Di Cosimo}, Serena and Milena Sant and Secondo Folli",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/0300891619867845",
language = "English",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - High consistency between characteristics of primary intraductal breast cancer and subtype of subsequent ipsilateral invasive cancer

AU - Gennaro, Massimiliano

AU - Meneghini, Elisabetta

AU - Baili, Paolo

AU - Bravaccini, Sara

AU - Curcio, Annalisa

AU - De Santis, Maria Carmen

AU - Lozza, Laura

AU - Listorti, Chiara

AU - Di Cosimo, Serena

AU - Sant, Milena

AU - Folli, Secondo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Ductal carcinoma in situ (DCIS) is considered a morphologic precursor of invasive cancer and is often treated with adjuvant whole-breast irradiation and endocrine therapy, as if it were an invasive cancer. Our aim was to provide further support for treatment de-escalation or enrollment of such patients in active surveillance trials. Methods: We retrospectively analyzed data on patients with conservatively treated primary DCIS subsequently diagnosed with ipsilateral invasive breast cancer (IBC) at 2 comprehensive breast cancer centers. From their merged databases, we identified 50 cases with full details on tumor grade, hormone receptor expression, and HER2 amplification, for both the primary DCIS and the corresponding IBC, and we assessed the similarities and differences between the two. Results: Distributions of hormone receptors were similar in primary DCIS and IBC, while high-grade and HER2-positive status was less common in IBC than in primary DCIS. The positivity for estrogen receptors (ER) and well-differentiated or moderately differentiated morphology in the primary DCIS persisted in 90% of the matching IBC. Changes in progesterone receptor expression were slightly more common than those in ER expression. Overall consistency for the luminal-like receptors subtype was found in 90% of cases. Conclusion: The high consistency between the features of primary DCIS and those of subsequent IBC (in the rare but not negligible cases of local failure) should be borne in mind when considering the therapeutic options. Treatment de-escalation and accrual of patients for active surveillance trials could be appropriate for luminal-like precursors.

AB - Background: Ductal carcinoma in situ (DCIS) is considered a morphologic precursor of invasive cancer and is often treated with adjuvant whole-breast irradiation and endocrine therapy, as if it were an invasive cancer. Our aim was to provide further support for treatment de-escalation or enrollment of such patients in active surveillance trials. Methods: We retrospectively analyzed data on patients with conservatively treated primary DCIS subsequently diagnosed with ipsilateral invasive breast cancer (IBC) at 2 comprehensive breast cancer centers. From their merged databases, we identified 50 cases with full details on tumor grade, hormone receptor expression, and HER2 amplification, for both the primary DCIS and the corresponding IBC, and we assessed the similarities and differences between the two. Results: Distributions of hormone receptors were similar in primary DCIS and IBC, while high-grade and HER2-positive status was less common in IBC than in primary DCIS. The positivity for estrogen receptors (ER) and well-differentiated or moderately differentiated morphology in the primary DCIS persisted in 90% of the matching IBC. Changes in progesterone receptor expression were slightly more common than those in ER expression. Overall consistency for the luminal-like receptors subtype was found in 90% of cases. Conclusion: The high consistency between the features of primary DCIS and those of subsequent IBC (in the rare but not negligible cases of local failure) should be borne in mind when considering the therapeutic options. Treatment de-escalation and accrual of patients for active surveillance trials could be appropriate for luminal-like precursors.

KW - active surveillance

KW - breast cancer subtype

KW - Intraductal breast cancer

KW - invasive local relapse

KW - treatment de-escalation

UR - http://www.scopus.com/inward/record.url?scp=85071646678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071646678&partnerID=8YFLogxK

U2 - 10.1177/0300891619867845

DO - 10.1177/0300891619867845

M3 - Article

C2 - 31446852

AN - SCOPUS:85071646678

JO - Tumori

JF - Tumori

SN - 0300-8916

ER -